Published in Int J Cancer on June 01, 2008
DAMPening inflammation by modulating TLR signalling. Mediators Inflamm (2010) 3.29
Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. Dev Cell (2009) 2.41
Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol (2011) 2.41
Fibronectins in vascular morphogenesis. Angiogenesis (2009) 1.66
A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation. Nat Chem Biol (2010) 1.66
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther (2009) 1.12
Force-induced fibronectin assembly and matrix remodeling in a 3D microtissue model of tissue morphogenesis. Integr Biol (Camb) (2012) 0.99
A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer (2011) 0.94
Circulating fibronectin controls tumor growth. Neoplasia (2013) 0.92
The extra domain A of fibronectin increases VEGF-C expression in colorectal carcinoma involving the PI3K/AKT signaling pathway. PLoS One (2012) 0.89
8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland. MAbs (2013) 0.88
Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer (2009) 0.87
A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochem Cell Biol (2010) 0.85
Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies. Proc Natl Acad Sci U S A (2015) 0.84
Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection. Histochem Cell Biol (2010) 0.84
Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse. Arthritis Res Ther (2013) 0.84
Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3. PLoS One (2010) 0.84
The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. Br J Cancer (2013) 0.84
Recombinant renewable polyclonal antibodies. MAbs (2015) 0.83
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site. Immunol Rev (2016) 0.82
Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids. Invest New Drugs (2015) 0.81
Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Hum Vaccin Immunother (2012) 0.81
Tumour-targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3. Eur J Nucl Med Mol Imaging (2010) 0.81
The TLR4 agonist fibronectin extra domain A is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine. Sci Rep (2015) 0.80
Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis. Proc Natl Acad Sci U S A (2014) 0.80
Identification and characterization of a unique role for EDB fibronectin in phagocytosis. J Mol Med (Berl) (2015) 0.80
A novel synthetic naïve human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin. MAbs (2011) 0.80
A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol (2011) 0.80
A highly functional synthetic phage display library containing over 40 billion human antibody clones. PLoS One (2014) 0.80
Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. Drug Discov Today (2015) 0.79
Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates. Mol Cancer Ther (2015) 0.79
Site-specific chemical modification of antibody fragments using traceless cleavable linkers. Nat Protoc (2013) 0.79
A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer. MAbs (2014) 0.78
Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery. Histochem Cell Biol (2011) 0.78
Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis. Histochem Cell Biol (2011) 0.78
Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets. Mol Genet Genomics (2015) 0.76
Therapeutic radionuclides in nuclear medicine: current and future prospects. J Zhejiang Univ Sci B (2014) 0.76
Detection of Soluble ED-A(+) Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling. Dis Markers (2016) 0.76
Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins. J Biol Chem (2016) 0.75
Different tissue distribution properties for glycosylation variants of fusion proteins containing the p40 subunit of murine interleukin-12. Protein Eng Des Sel (2016) 0.75
Selection and Characterization of Single Chain Antibody Fragments Specific for Hsp90 as a Potential Cancer Targeting Molecule. Int J Mol Sci (2015) 0.75
From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform. Int J Mol Sci (2017) 0.75
Irigenin, a novel lead from Western Himalayan chemiome inhibits Fibronectin-Extra Domain A induced metastasis in Lung cancer cells. Sci Rep (2016) 0.75
Counterbalancing anti-adhesive effects of Tenascin-C through fibronectin expression in endothelial cells. Sci Rep (2017) 0.75
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 1.66
A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation. Nat Chem Biol (2010) 1.66
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med (2006) 1.62
Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer (2002) 1.53
The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol (2012) 1.46
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2014) 1.45
Fibronectin as target for tumor therapy. Int J Cancer (2006) 1.44
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood (2008) 1.42
Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics (2005) 1.42
Encoded self-assembling chemical libraries. Nat Biotechnol (2004) 1.40
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods (2005) 1.32
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res (2003) 1.31
Selective targeted delivery of TNFalpha to tumor blood vessels. Blood (2003) 1.29
Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res (2011) 1.27
The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res (2007) 1.26
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res (2006) 1.23
Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today (2012) 1.20
High-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical libraries. Proc Natl Acad Sci U S A (2008) 1.18
Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release (2012) 1.18
The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res (2007) 1.14
Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study. Proteomics (2004) 1.14
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol (2002) 1.12
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther (2009) 1.12
In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography. Cancer Res (2010) 1.10
Isolation of high-affinity trypsin inhibitors from a DNA-encoded chemical library. Angew Chem Int Ed Engl (2007) 1.10
Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta (2007) 1.08
Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics (2004) 1.08
Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer (2005) 1.06
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer (2010) 1.05
A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics (2006) 1.03
Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer (2008) 1.03
Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol (2013) 1.01
DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries. Acc Chem Res (2014) 1.01
Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res (2003) 1.01
Identification of a novel cell binding site of periostin involved in tumour growth. Eur J Cancer (2011) 1.01
Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res (2008) 1.01
Molecular targeting of angiogenesis. Biochim Biophys Acta (2004) 1.00
Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med (2006) 1.00
In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett (2009) 0.99
In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood (2009) 0.99
Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res (2004) 0.99
(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging (2009) 0.99
Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther (2007) 0.99
20 years of DNA-encoded chemical libraries. Chem Commun (Camb) (2011) 0.99
Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel (2006) 0.98
Lead discovery by DNA-encoded chemical libraries. Drug Discov Today (2007) 0.98
Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res (2006) 0.96
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res (2011) 0.96
Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries. Angew Chem Int Ed Engl (2013) 0.96
Selection of streptavidin binders from a DNA-encoded chemical library. Bioconjug Chem (2006) 0.95
Sequence determinants of a microtubule tip localization signal (MtLS). J Biol Chem (2012) 0.95
Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. J Am Chem Soc (2012) 0.95
A portable albumin binder from a DNA-encoded chemical library. Angew Chem Int Ed Engl (2008) 0.95
Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping. Proteomics (2005) 0.95
Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem (2002) 0.94
Selection of Carbonic Anhydrase IX Inhibitors from One Million DNA-Encoded Compounds. ACS Chem Biol (2011) 0.93
New strategy for the extension of the serum half-life of antibody fragments. Bioconjug Chem (2009) 0.93
Design and synthesis of a novel DNA-encoded chemical library using Diels-Alder cycloadditions. Bioorg Med Chem Lett (2008) 0.93
Selection of single domain binding proteins by covalent DNA display. Protein Eng Des Sel (2007) 0.92
The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res (2012) 0.92
Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping. FASEB J (2008) 0.92
Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope (2003) 0.92
Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res (2009) 0.92
Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies. Atherosclerosis (2009) 0.92
In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature. Nat Protoc (2006) 0.92
A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl (2014) 0.92
Comparative analysis of the membrane proteome of closely related metastatic and nonmetastatic tumor cells. Cancer Res (2009) 0.92
Antibody-based vascular tumor targeting. Recent Results Cancer Res (2010) 0.92
A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl (2011) 0.91
DNA-encoded chemical libraries for the discovery of MMP-3 inhibitors. Bioconjug Chem (2008) 0.91